Suchergebnisse - "Lervat, Cyril"

PubPharm (6)

1

Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France

enthalten in: International journal of cancer | 2023

von Corvest, V. | Marec-Bérard, P. | Lervat, C. | +25

2

Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050) : a multicentre, open-label, multicohort, phase 1/2 study

enthalten in: The Lancet. Oncology | 2021

von Gaspar, N. | Venkatramani, R. | Hecker-Nolting, S. | +19

CommentIn: Lancet Oncol. 2021 Sep;22(9):1206-1207. - PMID 34416160

3

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years

enthalten in: Journal of adolescent and young adult oncology | 2020

von Marec-Berard, P. | Laurence, V. | Occean, B. | +17

4

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Gaspar, N. | Occean, B. | Pacquement, H. | +24

5

Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients

enthalten in: Bulletin du cancer | 2017

von Stern, N. | Sakji, I. | Defachelles, A. | +6

6

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006) : a randomised, multicentre, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2016

von Piperno-Neumann, S. | Le Deley, M. | Rédini, F. | +23

CommentIn: Lancet Oncol. 2016 Aug;17 (8):1022-1023. - PMID 27511145

1
[1]